The ZIP4 pathway in pancreatic cancer

Cancer Biology and Therapy

Volumn 9, Issue 3, 2010, Pages 242-244

  Donahue, Timothy ^a   Hines, O Joe ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Irt like proteins; Matrix metalloproteins 2 and 9 (MMP2 and MMP9); Neuropilin 1 (NRP 1); Pancreatic cancer; Vascular endothelial growth factor (VEGF); Zrt

Indexed keywords

GELATINASE A; GELATINASE B; NEUROPILIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; ZINC TRANSPORTER; ZIP4 PROTEIN;

CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; DISEASE ASSOCIATION; GENE; HUMAN; NOTE; PANCREAS CANCER; PROTEIN EXPRESSION; XENOGRAFT; ZINC METABOLISM;

EID: 77953598990     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.3.11064     Document Type: Note

References (18)

1. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 2008; 143:1166-71.
2. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2009; 4:CD002093.
3. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6.
4. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995; 18:1-6.
5. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57:3126-30.
6. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-3.
7. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33. (Pubitemid 24187791)
8. Li M, Zhang Y, Liu Z, Bharadwaj U, Wang H, Wang X, et al. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci USA 2007; 104:18636-41.
9. Garcea G, Doucas H, Steward WP, Dennison AR, Berry DP. Hypoxia and angiogenesis in pancreatic cancer. ANZ J Surg 2006; 76:830-42.
10. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63:2649-57. (Pubitemid 36605209)
11. Fujisawa H, Kitsukawa T. Receptors for collapsin/semaphorins. Curr Opin Neurobiol 1998; 8:587-92.
12. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 2005; 65:3664-70. (Pubitemid 40616343)
13. Li M, Yang H, Chai H, Fisher WE, Wang X, Brunicardi FC, et al. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 2004; 101:2341-50.
14. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 1995; 55:3964-8.
15. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 2003; 98:720-9. (Pubitemid 36959267)
16. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19:1118-27. (Pubitemid 32176289)
17. Jimenez RE, Hartwig W, Antoniu BA, Compton CC, Warshaw AL, Fernandez-Del Castillo C. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control. Ann Surg 2000; 231:644-54.
18. Haq M, Shafii A, Zervos EE, Rosemurgy AS. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res 2000; 60:3207-11.